Tumor immune microenvironment plays a crucial role in determining the effectiveness of PD-1 immunotherapy, with the expression level of PD-L1 in tumor cells and the density and phenotype of tumor-infiltrating T lymphocytes being important factors [23, 24]. The gene discussed is CD274; the disease is neoplasm.